194 related articles for article (PubMed ID: 27837711)
1. Paramagnetic bradykinin analogues as substrates for angiotensin I-converting enzyme: Pharmacological and conformation studies.
Teixeira LG; Malavolta L; Bersanetti PA; Schreier S; Carmona AK; Nakaie CR
Bioorg Chem; 2016 Dec; 69():159-166. PubMed ID: 27837711
[TBL] [Abstract][Full Text] [Related]
2. Conformational Properties of Seven Toac-Labeled Angiotensin I Analogues Correlate with Their Muscle Contraction Activity and Their Ability to Act as ACE Substrates.
Teixeira LG; Malavolta L; Bersanetti PA; Schreier S; Carmona AK; Nakaie CR
PLoS One; 2015; 10(8):e0136608. PubMed ID: 26317625
[TBL] [Abstract][Full Text] [Related]
3. Analogues containing the paramagnetic amino acid TOAC as substrates for angiotensin I-converting enzyme.
de Deus Teixeira LG; Bersanetti PA; Schreier S; Carmona AK; Nakaie CR
FEBS Lett; 2007 May; 581(13):2411-5. PubMed ID: 17485083
[TBL] [Abstract][Full Text] [Related]
4. Conformational basis for the biological activity of TOAC-labeled angiotensin II and bradykinin: electron paramagnetic resonance, circular dichroism, and fluorescence studies.
Schreier S; Barbosa SR; Casallanovo F; Vieira Rde F; Cilli EM; Paiva AC; Nakaie CR
Biopolymers; 2004 Aug; 74(5):389-402. PubMed ID: 15222018
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of angiotensin converting enzyme and potentiation of bradykinin by retro-inverso analogues of short peptides and sequences related to angiotensin I and bradykinin.
Carmona AK; Juliano L
Biochem Pharmacol; 1996 Apr; 51(8):1051-60. PubMed ID: 8866827
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and pharmacological properties of TOAC-labeled angiotensin and bradykinin analogs.
Nakaie CR; Silva EG; Cilli EM; Marchetto R; Schreier S; Paiva TB; Paiva AC
Peptides; 2002 Jan; 23(1):65-70. PubMed ID: 11814619
[TBL] [Abstract][Full Text] [Related]
7. Do the cardiovascular effects of angiotensin-converting enzyme (ACE) I involve ACE-independent mechanisms? new insights from proline-rich peptides of Bothrops jararaca.
Ianzer D; Santos RA; Etelvino GM; Xavier CH; de Almeida Santos J; Mendes EP; Machado LT; Prezoto BC; Dive V; de Camargo AC
J Pharmacol Exp Ther; 2007 Aug; 322(2):795-805. PubMed ID: 17475904
[TBL] [Abstract][Full Text] [Related]
8. Functional assessment of angiotensin II and bradykinin analogues containing the paramagnetic amino acid TOAC.
Santos EL; de Picoli Souza K; Sabatini RA; Martin RP; Fernandes L; Nardi DT; Malavolta L; Shimuta SI; Nakaie CR; Pesquero JB
Int Immunopharmacol; 2008 Feb; 8(2):293-9. PubMed ID: 18182243
[TBL] [Abstract][Full Text] [Related]
9. Potentiation of the effects of bradykinin on its receptor in the isolated guinea pig ileum.
Minshall RD; Nedumgottil SJ; Igić R; Erdös EG; Rabito SF
Peptides; 2000 Aug; 21(8):1257-64. PubMed ID: 11035213
[TBL] [Abstract][Full Text] [Related]
10. Potentiation of bradykinin effect by angiotensin-converting enzyme inhibition does not correlate with angiotensin-converting enzyme activity in the rat mesenteric arteries.
Sivieri DO; Bispo-da-Silva LB; Oliveira EB; Resende AC; Salgado MC
Hypertension; 2007 Jul; 50(1):110-5. PubMed ID: 17470724
[TBL] [Abstract][Full Text] [Related]
11. Demonstration of extrapulmonary activity of angiotensin converting enzyme in intact tissue preparations.
Lembeck F; Griesbacher T; Eckhardt M
Br J Pharmacol; 1990 May; 100(1):49-54. PubMed ID: 2164861
[TBL] [Abstract][Full Text] [Related]
12. Roles of the two active sites of somatic angiotensin-converting enzyme in the cleavage of angiotensin I and bradykinin: insights from selective inhibitors.
Georgiadis D; Beau F; Czarny B; Cotton J; Yiotakis A; Dive V
Circ Res; 2003 Jul; 93(2):148-54. PubMed ID: 12805239
[TBL] [Abstract][Full Text] [Related]
13. Selectivity of converting-enzyme inhibitors for angiotensin I versus bradykinin hydrolysis reactions.
Brooks RR; Miller KE; Jones SM; Burns RH; Huang CT
J Pharm Sci; 1990 May; 79(5):384-8. PubMed ID: 2161922
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological activities of new side chain and backbone cyclic bradykinin analogues.
Schumann C; Seyfarth L; Greiner G; Paegelow I; Reissmann S
J Pept Res; 2002 Aug; 60(2):128-40. PubMed ID: 12102726
[TBL] [Abstract][Full Text] [Related]
15. Contribution of angiotensin-converting enzyme to the cardiac metabolism of bradykinin: an interspecies study.
Blais C; Drapeau G; Raymond P; Lamontagne D; Gervais N; Venneman I; Adam A
Am J Physiol; 1997 Nov; 273(5):H2263-71. PubMed ID: 9374762
[TBL] [Abstract][Full Text] [Related]
16. Discrimination between putative bradykinin B2 receptor subtypes in guinea pig ileum smooth muscle membranes with a selective, iodinatable, bradykinin analogue.
Liebmann C; Bossé R; Escher E
Mol Pharmacol; 1994 Nov; 46(5):949-56. PubMed ID: 7969085
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo characterization of bradykinin B2 receptors in the rabbit and the guinea pig.
Gobeil F; Filteau C; Pheng LH; Jukic D; Nguyen-Le XK; Regoli D
Can J Physiol Pharmacol; 1996 Feb; 74(2):137-44. PubMed ID: 8723025
[TBL] [Abstract][Full Text] [Related]
18. Short peptide constructs mimic agonist sites of AT(1)R and BK receptors.
Lopes DD; Vieira RF; Malavolta L; Poletti EF; Shimuta SI; Paiva AC; Schreier S; Oliveira L; Nakaie CR
Amino Acids; 2013 Mar; 44(3):835-46. PubMed ID: 23096780
[TBL] [Abstract][Full Text] [Related]
19. Biologic activities of iodinated analogues of Tyr0-bradykinin and bradykinin-Ile10-Tyr11 assessed in the rat uterus and the guinea pig ileum.
Cunha V; Gutierrez J; Corrêa FM
Gen Pharmacol; 1996 Jul; 27(5):787-94. PubMed ID: 8842680
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological properties of the new non-sulfhydryl angiotensin converting enzyme inhibitor N-[8-amino-1(S)-carboxyoctyl]-L-alanyl-L-proline.
Shirota M; Kajiwara Y; Iijima M; Kitabatake K
Arzneimittelforschung; 1990 May; 40(5):515-9. PubMed ID: 2166521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
